Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,…
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,…
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,…
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in…
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in…
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in…
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in…
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in…
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in…
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for…